These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23348212)

  • 1. Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation.
    Liu Q; Galli S; Srinivasan R; Linehan WM; Tsokos M; Merino MJ
    Am J Surg Pathol; 2013 Mar; 37(3):368-74. PubMed ID: 23348212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SMARCB1/INI1 inactivation in renal medullary carcinoma.
    Calderaro J; Moroch J; Pierron G; Pedeutour F; Grison C; Maillé P; Soyeux P; de la Taille A; Couturier J; Vieillefond A; Rousselet MC; Delattre O; Allory Y
    Histopathology; 2012 Sep; 61(3):428-35. PubMed ID: 22686875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior.
    Cheng JX; Tretiakova M; Gong C; Mandal S; Krausz T; Taxy JB
    Mod Pathol; 2008 Jun; 21(6):647-52. PubMed ID: 18327209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of SMARCB1/INI-1 expression in collecting duct carcinoma.
    Elwood H; Chaux A; Schultz L; Illei PB; Baydar DE; Billis A; Sharma R; Argani P; Epstein JI; Netto GJ
    Urology; 2011 Aug; 78(2):474.e1-5. PubMed ID: 21705046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biphasic alveolosquamoid renal carcinoma: a histomorphological, immunohistochemical, molecular genetic, and ultrastructural study of a distinctive morphologic variant of renal cell carcinoma.
    Petersson F; Bulimbasic S; Hes O; Slavik P; Martínek P; Michal M; Gomolčáková B; Hora M; Damjanov I
    Ann Diagn Pathol; 2012 Dec; 16(6):459-69. PubMed ID: 23036259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
    Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
    Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases.
    Michalova K; Steiner P; Alaghehbandan R; Trpkov K; Martinek P; Grossmann P; Montiel DP; Sperga M; Straka L; Prochazkova K; Cempirkova D; Horava V; Bulimbasic S; Pivovarcikova K; Daum O; Ondic O; Rotterova P; Michal M; Hora M; Hes O
    Ann Diagn Pathol; 2018 Aug; 35():1-6. PubMed ID: 30072012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [SMARCB1(INI1)-deficient renal cell carcinoma: medullary and beyond : Evolving concepts].
    Agaimy A; Hartmann A
    Pathologe; 2021 Nov; 42(6):571-577. PubMed ID: 34609565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases.
    Jia L; Carlo MI; Khan H; Nanjangud GJ; Rana S; Cimera R; Zhang Y; Hakimi AA; Verma AK; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE; Gartrell BA; Chen YB
    Mod Pathol; 2019 Sep; 32(9):1329-1343. PubMed ID: 30980040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathology and diagnosis of SMARCB1-deficient tumors.
    Margol AS; Judkins AR
    Cancer Genet; 2014 Sep; 207(9):358-64. PubMed ID: 25246033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.
    Ohe C; Smith SC; Sirohi D; Divatia M; de Peralta-Venturina M; Paner GP; Agaimy A; Amin MB; Argani P; Chen YB; Cheng L; Colecchia M; Compérat E; Werneck da Cunha I; Epstein JI; Gill AJ; Hes O; Hirsch MS; Jochum W; Kunju LP; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Nesi G; Osunkoya AO; Picken MM; Rao P; Reuter VE; de Oliveira Salles PG; Schultz L; Tickoo SK; Tomlins SA; Trpkov K; Amin MB
    Am J Surg Pathol; 2018 Mar; 42(3):279-292. PubMed ID: 29309300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases.
    Petersson F; Gatalica Z; Grossmann P; Perez Montiel MD; Alvarado Cabrero I; Bulimbasic S; Swatek A; Straka L; Tichy T; Hora M; Kuroda N; Legendre B; Michal M; Hes O
    Virchows Arch; 2010 Apr; 456(4):355-65. PubMed ID: 20300772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma.
    Sirohi D; Smith SC; Ohe C; Colombo P; Divatia M; Dragoescu E; Rao P; Hirsch MS; Chen YB; Mehra R; Amin MB
    Hum Pathol; 2017 Sep; 67():134-145. PubMed ID: 28716439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas.
    Calderaro J; Masliah-Planchon J; Richer W; Maillot L; Maille P; Mansuy L; Bastien C; de la Taille A; Boussion H; Charpy C; Jourdain A; Bléchet C; Pierron G; Gentien D; Choudat L; Tournigand C; Delattre O; Allory Y; Bourdeaut F
    Eur Urol; 2016 Jun; 69(6):1055-61. PubMed ID: 26433572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21).
    Argani P; Antonescu CR; Couturier J; Fournet JC; Sciot R; Debiec-Rychter M; Hutchinson B; Reuter VE; Boccon-Gibod L; Timmons C; Hafez N; Ladanyi M
    Am J Surg Pathol; 2002 Dec; 26(12):1553-66. PubMed ID: 12459622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case report.
    Yu L; Li J; Xu S; Navia Miranda M; Wang G; Duan Y
    Diagn Pathol; 2016 Oct; 11(1):98. PubMed ID: 27733182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions and clinicopathologic associations.
    Altinok G; Kattar MM; Mohamed A; Poulik J; Grignon D; Rabah R
    Pediatr Dev Pathol; 2005; 8(2):168-80. PubMed ID: 15747097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR.
    Argani P; Laé M; Hutchinson B; Reuter VE; Collins MH; Perentesis J; Tomaszewski JE; Brooks JS; Acs G; Bridge JA; Vargas SO; Davis IJ; Fisher DE; Ladanyi M
    Am J Surg Pathol; 2005 Feb; 29(2):230-40. PubMed ID: 15644781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 1 papillary renal cell carcinoma in a patient with schwannomatosis: Mosaic versus loss of SMARCB1 expression in respectively schwannoma and renal tumor cells.
    Hulsebos TJ; Kenter S; Baas F; Nannenberg EA; Bleeker FE; van Minkelen R; van den Ouweland AM; Wesseling P; Flucke U
    Genes Chromosomes Cancer; 2016 Apr; 55(4):350-4. PubMed ID: 26799435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warthin-like papillary renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 11 cases.
    Skenderi F; Ulamec M; Vanecek T; Martinek P; Alaghehbandan R; Foix MP; Babankova I; Montiel DP; Alvarado-Cabrero I; Svajdler M; Dubinský P; Cempirkova D; Pavlovsky M; Vranic S; Daum O; Ondic O; Pivovarcikova K; Michalova K; Hora M; Rotterova P; Stehlikova A; Dusek M; Michal M; Hes O
    Ann Diagn Pathol; 2017 Apr; 27():48-56. PubMed ID: 28325361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.